GSK 2010 Q3 results

Some pretty interesting things in the Q3 results: Sales are down 8% in the US and 9% in Europe. This is accounted for by a descrease in Avandia and Valtrex sales. While Avandia is their best known drug, it seems to only account for about 2% of their overall sales, largely because so much of what they sell internationally is of the immunization type. Three of their newest oncology used medicines counted for 2 million pounds (about $3,135,000). This company has some fantastic cash cows!!